



SOLID DOSE DRUG PROCEDURES

ABOUT THIS DOCUMENT

Procedures contained in this document are reviewed annually. Changes, if any, are acknowledged by staff. Obsolete / retired versions are archived and retained in the laboratory for at least two years.

TABLE OF CONTENTS

- I. Evidence Handling and Preservation**
 - A. Evidence Control
 - 1. Chain of Custody
 - B. Evidence Handling and Packaging
 - 1. Proper Handling
 - 2. Packaging

- II. Quality Control**
 - A. Equipment Maintenance and Calibration
 - B. Reagents, Standards, and Quality Control Materials
 - C. Quality Control
 - D. Criteria for Evaluation Blanks within GC/MS run
 - E. Policy for Reporting Uncertainty of Measurement

- III. General Case Handling Procedures**
 - A. General Observations
 - 1. Package Condition
 - 2. Identification Numbers
 - 3. Evidence Description
 - 4. Sealed Package Weight
 - 5. Gross Weight
 - B. Analysis
 - 1. Net Weight
 - 2. Evidence Sampling Plans
 - C. Identification Requirements
 - 1. Minimal Requirements for Complete Identification
 - 2. Minimal Requirements for Preliminary Identification

- IV. Case Documentation**
 - A. Case Notes
 - B. Case File

- V. General Analytical Procedures and Criteria for Evaluating Unknowns**
 - A. Thin Layer Chromatography
 - B. Gas Chromatography/Mass Spectrometry



SOLID DOSE DRUG PROCEDURES

C. Fourier Transform Infrared Spectroscopy

VI. Specific Analytical Procedures

- A. Cannabis/Hashish
- B. General Powders/Residues
- C. Tablets/Capsules/Films
- D. Suspected LSD
- E. Psilocybe Mushrooms
- F. Liquid Samples and Food Products
- G. Waste

VII. Appendices

- A. Operation and Maintenance of the GC-MS
- B. Operation and Maintenance of the FTIR



I. Evidence Handling and Preservation

A. EVIDENCE CONTROL

1. Chain-Of-Custody

At the time of receipt, each case will receive a laboratory identification number. Whenever possible, all pertinent information contained on the Receipt/Contract for Examination form will be completed with every submission to the HETL Forensic Chemistry Section (FCS). The receipt will be completed in triplicate and the copies distributed as follows:

- a. White copy (original) to submitter or case file
- b. Yellow copy to case file
- c. Pink copy placed in the appropriate file located in the evidence technician office.

The sealed package weight (SPW) will be taken and recorded on the evidence form along with a description of the evidence received. The sealed package weight (SPW) is the weight including the envelope, box, etc. containing the evidence.

The recipient will mark all evidence and corresponding paperwork for identification with the laboratory number. Evidence will be secured in either the evidence safe, evidence refrigerator, evidence freezers, evidence cabinet in the laboratory, or evidence room. Upon relinquishing control of evidence, transfers will be noted on the reverse side of the pink Receipt/Contract for Examination form. The back of the pink copy serves as the internal chain of custody document.

When placing evidence into Evidence Storage, the reverse side of the pink copy will be completed. Upon completion of the casefile the pink sheet will be placed in the accountability file located in the evidence technician office. This copy must be annotated each time someone removes and returns evidence from/to evidence storage. This includes intra-laboratory transfers. Once a case is completed, all pink sheets are maintained in the accountability file until such time as the evidence is returned or destroyed.

Evidence to be analyzed will be removed from evidence storage and brought directly into the laboratory for processing. A description of the item(s) and the condition of the packaging will be noted in the analyst's case notes.

Whenever possible, care should be taken to not cut, or break original evidence seals. However, it is recognized this is not always possible depending on packaging and placement of seals. During analysis the unsealed evidence will be under the control of the analyst. If the analyst must leave his/her work area for an extended period, all evidence will be placed in the analyst's lockbox or evidence cabinet or secured in some fashion. Samples, or aliquots, of the evidence will be taken for analysis. The samples/aliquots will not be tracked on the chain of custody during the testing process.



SOLID DOSE DRUG PROCEDURES

After analysis, the evidence will be returned to the original package, if possible, and sealed. Take care not to seal over any bar codes from the submitting agency to prevent issues with scanning upon return. Staples should be avoided to prevent piercing the heat sealed bags within the external envelope. If new packaging is required, which differs from the originally submitted exterior container, this change shall be noted on the chain of custody and analyst's worksheet. If items are separated or sub-items are created, these shall be documented on the analyst's worksheet and tracked on the chain of custody. The seal will be dated, signed, or initialed by the analyst and the post sealed package weight (pspw) recorded on the container and in the case notes. Processed evidence will be placed into evidence storage until final disposition. The reverse side of the pink receipt form will be completed and retained in the appropriate accountability file.

Upon final disposition (return to submitting agency or destruction), the Receipt/Contract for Examination Form will be removed from the accountability file and placed in the case folder.

B. Evidence Handling and Packaging

Preserving the integrity of evidence is crucial for proper interpretation and future admissibility at trial. Integrity of evidence is maintained through two practices:

1. Proper Handling
2. Proper Packaging

1. Proper Handling

All laboratory personnel will handle submitted materials in a manner that assures the integrity of the evidence. Prior to initiating and during the processing of evidence, the analyst will employ the following practices:

- The work area will be clean and free of excess debris –
 - Countertops are cleaned when dirty, or as needed by the Analyst
 - Trash is removed daily, or when necessary
- All glassware, tools, spatula's, etc used in conjunction with examining evidence will be clean.
- Test tubes, capillary pipettes and Pasteur pipettes are used only once, then discarded.
- To prevent cross contamination of samples, only one case will be opened and sampled by the analyst at a time. Additionally, in cases involving multiple submissions, only one item will be opened by the analyst at a time. This does not mean that multiple cases cannot be 'batched' for analysis, but rather, only 1 item of evidence shall be open at a time for sampling, manipulation, etc.
- All evidence will be stored under proper seal (see below).



SOLID DOSE DRUG PROCEDURES

- Reagents and solvents will be kept in closed containers, and labeled with identity, lot number, who prepared (if applicable), and any special storage requirements.

2. Proper Packaging

All evidence must be packaged in a manner that ensures its integrity. Therefore, all evidence must be retained under proper seal. **Proper seal** is defined as: containers sealed to prevent the loss of contents and secured in a manner such that entering the container results in obvious damage or alterations to the container's seal. Evidence that is actively being examined by an analyst need not always be sealed, but shall be secured when not actively being sampled, analyzed, etc.

After the exhibit has been sampled for analysis, the exhibit will be re-packaged. The analyst will seal the container with evidence tape, place their initials and date across the tape seal.



II. QUALITY ASSURANCE

A. Equipment Maintenance and Calibration

Refer to Appendix A, Appendix B, and the Quality Manual.

B. Reagents, Standards, and Quality Control Materials

Standards purchased from an approved vendor shall be used for comparison for identifications and confirmations. Refer to SOP Manual and Quality Manual for standard use and handling requirements. DEA non-exempt controlled substance standards have special inventory and destruction requirements. It is the analyst's responsibility to ensure proper handling and storage of all standards.

The SDD GC/MS process for standard evaluation and approval is as follows:

- All compounds should be named using the following convention
[COMPOUND NAME] [LOT NUMBER] Exp:[DDMMYY] Run:[DDMMYY]
- New Compounds
 - A Certificate of Analysis shall be obtained from the vendor specific to that lot number.
 - **Reference Spectra:** The standard shall be run on each appropriate analysis method and instrument, used to update the reference spectra and retention time, and added to the Quant QEdit list. A print off from each analysis method and instrument shall be provided to the Quality Manager for review.
 - **Library Entry:** The standard shall be compared to an approved external GC/MS library and achieve a library match of 80 or greater, prior to the standard being added to the HETL library. If an acceptable library match is achieved the standard shall be added to the HETL library using the *Compound Name, Lot Number and Expiration Date* as the entry name. A print off of the external library match shall be provided to the Quality Manager for review.
 - The Quality Manager shall review each packet to ensure the lot number, expiration date, retention time, library comparison and library entry are acceptable. The standard will be entered into the tracking excel sheet and a PDF of the packet will be saved on the K drive for easy reference.
- New Lot Number of Existing Compounds
 - A Certificate of Analysis shall be obtained from the vendor specific to that lot number.
 - **Reference Spectra:** The standard shall be run on each appropriate analysis method and instrument, used to update the reference spectra and retention time, and updated on the Quant QEdit list. A print off of at least one analysis method from both instruments shall be provided to the Quality Manager for review.



SOLID DOSE DRUG PROCEDURES

- **Library Entry:** The standard shall be compared to an approved external GC/MS library and achieve a library match of 80 or greater, prior to the standard being added to the HETL library using the compound name, lot number and expiration date as the entry name. If an acceptable library match is achieved the standard shall be added to the HETL library. A print off of the external library match shall be provided to the Quality Manager for review.
- The Quality Manager shall review each packet to ensure the lot number, expiration date, retention time, library comparison and library entry are acceptable. The standard will be entered into the tracking excel sheet and a PDF of the packet will be saved on the K drive for easy reference.

The SDD FTIR process for standard evaluation and approval is as follows:

- **New Compounds and New Lot Number of Existing Compounds**
 - A Certificate of Analysis shall be obtained from the vendor specific to that lot number.
 - The standard shall be run the appropriate analysis method, compared to an approved external FTIR library, and achieve a library match of 80 or greater, prior to the standard being added to the HETL library. If an acceptable library match is achieved the standard shall be added to the HETL library using the *Compound Name, Lot Number and Expiration Dat* as the entry name. A print off of the standard spectra and external library match shall be provided to the Quality Manager for review.
 - The Quality Manager shall review each packet to ensure the lot number, expiration date, library comparison and library entry are acceptable. The standard will be entered into the tracking excel sheet and a PDF of the packet will be saved on the K drive for easy reference.

Refer to specific analysis procedure, SDD Reagent Logs, and the Quality Manual for more information regarding reagents and quality control measures.

C. QUALITY CONTROL

Functional checks will be performed to check the performance of equipment and reagents used (either at regular intervals or while testing samples). Control checks will be performed during the analysis or testing process. These checks are used to:

- Determine the performance of the analytical or testing system.
- Quantitate (if possible) the variability of results from the analysis or test in terms of precision and accuracy.

The data from the check analyses will be compared with the expected values. Any significant difference (as determined by the analyst) shall be reported to the Section Supervisor.



SOLID DOSE DRUG PROCEDURES

To determine the proper operation of the balances, weekly and daily checks will be performed using a calibrated weight set. The weight set should be calibrated to at least a Class II requirement or higher. Results will be recorded on the balance check worksheet. Weekly checks will be done using a range of weights that covers the applied use of the balance and daily checks will be done using one lower mass and one higher mass, as outlined on the balance check sheet. Checks shall only be required on balances used to report out weights on days/weeks when the balance is in use.

To determine the proper operation of the GC/MS and/or lack of solvent contamination, the analyst will run and evaluate a blank containing the Internal Standard and appropriate solvent, if applicable, between each case sample. The volumes of internal standard and solvents for the blank should be prepared as close to the sample preparation as possible.

To determine the lack of contamination during multisolvent (complex) extractions, one procedural extraction blank per extraction set will undergo each step of the extraction procedure, alongside the samples, prepared the same as the samples for GC/MS analysis, and run under the same GC/MS conditions as the sample.

Evaluation of blanks is used to determine if a sample needs to be re-run or if there is a need for instrument maintenance. A clean blank and procedure blank, when applicable, is required for confirmation of a controlled substance.

D. CRITERIA FOR EVALUATING BLANKS IN GC/MS ANALYSIS

An acceptable blank will be evaluated using the same instrument method as the sample, and contain no target compounds as listed on the Quant QEdit Report for the method used and/or other compounds, at the discretion of the analyst, having a signal to noise ratio of greater than 3:1. An internal standard peak must be present in the blank meeting all acceptability criteria outlined in section V-B-2 of this manual. It is noted that a minor secondary peak has historically been present in the DFTPP blank with a signal to noise ratio >3:1 containing ions 271 m/z, 290 m/z, 438 m/z, and 458 m/z. The analyst should evaluate this peak during analysis to ensure it is not a target compound, however no remedial action or additional documentation in the casefile is required if this secondary peak is present in a DFTPP blank at a signal to noise > 3:1. If a standard is updated for a sample, following the evaluation of the corresponding blank, the blank must be reprocessed, along with the sample, for proper evaluation.

In cases where the blank fails these criteria, the subsequent case sample vial will be re-run and/or re-extracted. The analyst will indicate on the printout that the sample is being rejected (or similar terminology), why the sample is rejected, the date of rejection, and the initials of the analyst. Failed blanks will be retained in the case file.



SOLID DOSE DRUG PROCEDURES

E. POLICY FOR REPORTING UNCERTAINTY OF MEASUREMENTS

When estimating the uncertainty of measurement, all uncertainty components which are of importance shall be taken into account using appropriate testing procedures. Refer to the SDD UoM Procedure for details.

Single weighing events: A single weighing event is defined as placing the empty weighing vessel onto the balance and obtaining a 'tare', and then adding the measurand (item to be weighted) to the vessel while it remains on the balance and recording the net weight. The uncertainty will be reported based upon the calculated total uncertainty specific to the balance used at 95.45%, K=2.

Multiple weighing events: Multiple weighing events are defined as placing the empty weighing vessel on the balance and obtaining a 'tare', removing the vessel from the balance, adding the measurand, and then returning the vessel with measurand to the balance to obtain the net weight. The uncertainty reported is the calculated total uncertainty specific to the balance used (standard uncertainty/ $U \times 2$ or expanded uncertainty)(# of items being considered)(# of weighing events). The result is expressed at 95.45%, K=2.

Combining weight to report a total weight of multiple single weighing events or multiple events: When multiple weights are combined to represent a single weight, the uncertainty reported is the sum of the total expanded uncertainty for each weighing event, or the most conservative number of weighing events is applied to all samples weighed for that item.

Additional information related to UofM in Solid Dose Drug Chemistry is contained in the "Solid Dose Drug UofM Procedures Document", on file with the Quality Manager and on SharePoint. Additionally, the Quality Manager has Certificates of Calibration for each balance used to report Solid Dose Drug net weights, repeatability data, and verified calculations related to final reporting values of UofM on each balance.



SOLID DOSE DRUG PROCEDURES

III. GENERAL CASE HANDLING PROCEDURES

A. GENERAL OBSERVATIONS

1. Package Condition

The analyst will note the condition of the evidence package: i.e.: Sealed or Unsealed. Initials should be present across the seal of the packaging. If initials are not present it shall be noted in the case folder.

2. Identification Numbers

The analyst will ensure all identification numbers agree with the chain of custody receipt (Receipt/Contract for Examination form).

The analyst will document the HETL case number and, if applicable, the submitting agency's item number in the case notes.

3. Evidence Description

When applicable, the analyst will ensure evidence description(s) reasonably agree with the description provided by the submitting agency. The purpose of identifying a discrepancy is to ensure the correct piece of evidence was submitted, the correct piece of evidence is being examined, and the evidence has not been compromised in any way prior to analysis.

If a minor discrepancy is found the analyst will continue with testing and the evidence description on the Certificate of Analysis will serve as customer notification of the discrepancy. Examples of a minor discrepancy may include:

- evidence was submitted listing 58 white tablets and the analyst counted 57 white tablets
- evidence was submitted as 8 tied bag corners of white powder and the analyst counted 10 tied bag corners of white powder
- evidence was submitted as 950 envelopes of tan powder and the analyst counted 943 envelopes of tan powder
- evidence was submitted as a bag of tan powder and the analyst found a bag of tan powder, a lighter, and an empty bag with residue

These examples demonstrate evidence that still reasonably agrees with the submitters description and no action is required by the analyst.

If a major discrepancy exists between evidence descriptions no testing will be conducted until reconciliation between the analyst and the submitter (or their representative) is accomplished. Examples of a major discrepancy may include:



SOLID DOSE DRUG PROCEDURES

- evidence was submitted listing 58 white tablets and the analyst counted 3 green tablets
- evidence was submitted as 8 tied bag corners of white powder and the analyst counted 1 bag of tan powder
- evidence was submitted as 950 envelopes of tan powder and the analyst counted 1500 envelopes of tan powder
- evidence was submitted as a bag of tan powder and the analyst found a bag of green plant material

NOTE: refer to Quality Manual regarding the procedures for addressing evidence discrepancies

The analyst will include a general description of the submitted evidence. The description will include the type of container and its contents. Abbreviated descriptions (i.e.: OSEE = One Sealed Evidence Envelope) may be used in the description. Abbreviated descriptions must be interpretable by other staff Chemists. A list of abbreviations is maintained on SharePoint. Common abbreviations such as g for gram are viewed as common knowledge, should be readily recognized by another qualified analysts, and need not be explicitly detailed in the abbreviations document. Chemical abbreviations are maintained in the HETL Chemical Hygiene Plan.

If the item is difficult to describe or a more detailed description is necessary, the analyst may document the item by sketching it in their notes, or by taking a picture using a state controlled camera (not a personal camera or cell phone). If a picture is taken, a ruler shall be included in the photo. The photo shall be printed for the case file and have the following items documented on the printout: HETL case number, item number(s), analyst initials, and date.

4. Sealed Package Weight

Sealed Package Weight = *the sealed package weight (SPW) is the weight including the envelope, box, etc. containing the evidence.*

The sealed package weight should be recorded in the case notes. Reconciliation action should be taken if, at the time of analysis, the evidence seals are not intact and/or the SPW of the sample differs significantly from the weight at the time of submission.

If seals are not intact or initialed a note will be made on the worksheet by the analyst and a description of the issue (seals were never intact, seals were intact but are now compromised, or seals are present but not initialed). If seals were never intact (ex: heat sealed bag never sealed or adhesive cover was never removed from bags with built in seals) a note will be made on the worksheet and reported on the Certificate of Analysis. If seals were damaged or compromised no testing will be conducted until another analyst reviews the packaging integrity and a reconciliation between the analyst and submitter is accomplished.



SOLID DOSE DRUG PROCEDURES

If the **SPW** differs significantly from the weight at the time of submission, no testing will be conducted until another analyst reviews packaging integrity or reconciliation between the analyst and the submitter (or their representative) is accomplished.

5. Gross Weight (if applicable)

Note: If the nature of the sample requires a net weight to be obtained, then (if possible) a gross weight will also be obtained.

Gross Weight = Gross weight will include any packaging directly touching the suspected drug.

Prior to beginning analysis, a **gross weight** of the drug submission will be obtained and written in the case notes.

B. ANALYSIS

1. Net Weight

Net Weight = the net weight is the weight of the drug specimen that includes no packaging.

The **net weight** of the drug sample will be obtained after removal of the drug from the package. The analyst should remove any extraneous debris from the sample prior to obtaining the net weight. This weight shall be recorded on the worksheet.

2. Reserve Weight

Reserve Weight = the weight of the drug specimen after sampling has occurred, but before it has been repackaged.

The reserve weight is to be taken by the analyst following sampling, but prior to repackaging. This weight shall be recorded on the worksheet.

3. Evidence Sampling Plan

Ideally, the evidence sampling requirements should be detailed at the time of submission or upon conference with the investigating officer or representative from the prosecutor's office (District Attorney/Attorney General). However, it is recognized that after analysis starts, and depending on the results, the sampling plan / approach may change. Changes, in the sampling plan will be documented within the case notes, and if significant, may require notification of the customer before the final report issued by the analyst.

When no specific sampling instructions have been provided by the client, the analyst may need to contact the customer to discuss the analysis and determine what type of sampling



SOLID DOSE DRUG PROCEDURES

is needed. Alternatively, it may be reasonable for the analyst to use their experience after examining the items to determine the best path for analysis at the least cost for the customer.

Sampling decisions in cases involving multiple similar items, or dosage units, may need to be based on either the Administrative sampling plan, or a statistically valid method that is recommended/accepted by major peer institutions (such as SWGDRUG, DEA or ASTM) if conclusions regarding the entire population are needed. It is recognized that the type of sampling may also vary based on the type of case (i.e., criminal charge), the number of submitted items, the total weight(s), and the wishes of the customer.

When the customer requests deviations, additions, or exclusions from the sampling methods, it shall be recorded in the case record with appropriate sampling data and test results. The final report to the customer shall be clear as to what was sampled and what the results are, and if they are specific to items tested, or if statistical conclusions regarding the entire population are associated with the analysis. A method deviation comment will be communicated on the case report. Any email or record of phone conversations with the customer regarding sampling will also be retained in the case record/file.

HETL will employ a multifaceted approach to examining submitted drug evidence: Including provisions to maximize the resources of the laboratory and to reduce the cost to the customer. This multifaceted approach will include components that include drug item reduction sampling, administrative sampling, and 2 levels of hypergeometric sampling. Each of which is detailed below.

Drug Item Reduction Program: The Drug Item Reduction Program allows for the analysis of probative items within a case to maximize the resources of the laboratory and to minimize the cost to the customer.

In every case, the most significant items in terms of quantity and schedule are analyzed. This “rule of thumb” cannot address every drug case scenario. Consideration must be given to the information contained on the Request for Laboratory Examination. This includes things such as the specific charges or types of offense, items unique to a single suspect, the statement of fact and examinations requested, and the descriptions of evidence submitted as well as the chemist’s visual inspection of the items and experience after opening and viewing all contents and documents associated with the case.

If at a later date it becomes apparent that items not initially analyzed require analysis for successful prosecution, then upon re-submission and/or request, that item(s) will receive top priority at the laboratory.



SOLID DOSE DRUG PROCEDURES

Procedures related to Drug Item Reduction

Syringes should only be analyzed if it is the only item in the case and has been specifically requested by the customer.

Residues, cigarettes, or cigarette butts will not be analyzed when measurable quantities of the associated drugs are also included among the items submitted.

Pharmaceutical preparations should be visually examined using pharmaceutical identifiers and appropriate reference materials. If all items are visually consistent (one homogenous population), then 1 tablet will be confirmed. The report will indicate total number of tablets submitted, 1 tablet selected and found to contain 'xxx'.

If identical intact, marked pharmaceutical preparations (e.g., tablets or untampered capsules) are present in multiple items, full analysis is required for only one item. Those preparations not analyzed may be reported as "Not Analyzed" or "Visually consistent with..."

Partial pharmaceutical preparations need not be analyzed when intact pharmaceutical preparations or measurable quantities of the same drug(s) are present. Analysis of partial pharmaceuticals may be required if it is suspected that the partial pharmaceutical is of a higher penalty group than the other items.

Items not analyzed will be clearly documented in case notes, and where appropriate to understanding the results, may need to be included in the report sent to the customer.

Example 1: Submitted evidence includes a plastic bag corner containing tan powder and a 1cc syringe with 10 units of liquid. The tan powder would be analyzed, and the syringe would not.

Example 2: Submitted evidence includes five tablets containing oxycodone and a plastic straw section with residue. The tablets would be analyzed, and the straw section would not.

Example 3: Submitted evidence includes five tablets containing alprazolam and a plastic straw section with residue. The tablets would be analyzed, and the straw section would not unless information on the submission form indicates that the straw section was used for a different drug, or the residue is markedly different from the other material in the submission, or there is reason to believe that the residue from the straw is comprised of a drug in a higher penalty group.



SOLID DOSE DRUG PROCEDURES

Example 4: Submitted evidence includes a plastic bag of plant material and a glass tube smoking device with white residue. Both the plant material and the smoking device would be analyzed based on different penalty groups.

Administrative Sampling: The administrative sampling plan will be used in cases to answer a specific legal question(s), or when items that appear to be similar, involve drugs with weight thresholds. If more specimens than listed in the hypergeometric sampling plans need to be analyzed to meet the weight threshold, the customer may need to be contacted for consultation regarding the best approach to sampling.

Possession-Furnishing-Trafficking with/without weight thresholds:

If multiple items (or sub-items) are present in the case, and analysis of additional items will meet a weight threshold, then sufficient items to meet the threshold will be fully examined (confirmed).

If a weight threshold cannot be met by examining additional items, then the analyst shall select the largest item (sub-item) and confirm. All other items may be reported as untested, or the analyst may weigh the other items, report their weight on the report, but clearly indicating the confirmation (and associated weight) is specific to the item confirmed. If some items (sub-items) are residue, then as per the Drug Item Reduction Plan, these items need not be analyzed.

All remaining items will be left intact should further analysis be required.

Example 1: Item 1 is submitted with 4 sub-items (1.1-1.4). All 4 items appear identical and are suspected to be methamphetamine. Combined, the total weight will be far less than 14 grams, the weight threshold of methamphetamine. In this instance, the analyst would choose the largest sub-item (item 1.2) and confirm the presence of methamphetamine. The report would indicate that item 1 consisted of 4 sub-items (1.1-1.4) that item 1.2 was selected for analysis, weighed x.x grams, and contained methamphetamine. Items 1.1, 1.3 and 1.4 were not examined. Alternatively, the weights of sub-items 1.1, 1.3 and 1.4 could also be reported, but report must be clear that only item 1.2 was confirmed.

Example 2: Item 1 is submitted with 4 sub-items (1.1-1.4). All 4 items appear identical and are suspected to be methamphetamine. Combined, the total weight will exceed 14 grams, the weight threshold of methamphetamine. In this instance, the analyst would choose as many sub-items as necessary to push the weight over the 14 gram threshold. Each item is weighed and confirmed individually. The report would



SOLID DOSE DRUG PROCEDURES

indicate the total weight, and that each item was examined individually and contained methamphetamine.

IF sub-items are not uniform and/or NOT suspected to be identical, then full analysis must be conducted.

Example 3: Item 1 is submitted with 3 sub-items (1.1-1.3). Item 1.1 contains a white powder, item 1.2 contains a tan powder, and item 1.3 contains a yellow powder. In this example, all items would be individually weighed and confirmed. If any item is residue, and analysis of the other items has yielded a measurable weight, then the residue need not be examined unless there is high likelihood that the residue is of a higher penalty group. In this example, analyst discretion and would impact the sampling plan regarding examining or not examining the residue.

Hypergeometric / Statistical Sampling: If conclusions wish to be drawn regarding the entire population of a submitted item, then the item must be sampled and examined in accordance with one of the hypergeometric statistical sampling plans listed below. HETL will utilize 2 hypergeometric sampling plans. Commonly referred to as 95/90 and 95/50.

Sampling of Multiple Units:

- A. First determine the populations present in an item.
 - 1. Evaluate the number of units present in an item carefully.
 - 2. Visually inspect each of the units in the item carefully as well as any contents for homogeneity in size, color, packaging, markings, labeling and other characteristics. For analysis purposes, each intact piece of blotter pater shall be considered a unit.
 - 3. If after careful visual inspection it is determined that the contents of the units are homogenous, the population shall consist of all the units.
 - 4. If there are differences, segregate the units into individual groups, based upon such observed differences. Each group shall be analyzed as a separate population.
 - 5. If in the course of analysis, it becomes apparent that the population is not homogenous, new populations may be formed based upon individual chemical test results.

- B. Determine the net weight for the population (If needed).
 - 1. For smaller populations with packaging, this can be accomplished by obtaining a net weight of each unit and summing for a total net weight.
 - 2. For larger populations, an estimate for net weight can be calculated using a gross weight of all units (including packaging) and a total tare weight based on the tare weight of one or more packages).



SOLID DOSE DRUG PROCEDURES

- C. Determine whether the net weight exceeds a statutory threshold. If so, the administrative sampling plan may be more appropriate and cost effective for the customer.
- D. If the net weight does not exceed a threshold, or if the case is being charged as a trafficking offense based on the number of dosage units (and not a weight threshold), and/or the customer wishes to conclude that more than the number of packages actually tested contains a controlled substance, then an appropriate number of items will be randomly selected from each population and fully analyzed to confirm the presence (or absence) of any controlled substance. See tables A and B below for specific numbers of samples to be examined based on the total number of items within each population.
- E. The difference between the 2 statistical sampling plans (Table A and B) relates to statistical significance that can be associated with each. An example of terminology that appears on reports using each is included in an example immediately following each table:

Table A: (95 /90) This sampling plan assures with 95% confidence that at least 90% of the entire population contains the substance identified in the sample.

Number of Units	Number sampled
10	8
11-20	12
21-30	15
31-40	18
41-50	19
51-60	20
61-70	21
71-80	22
81-100	23
101-200	26
201-400	27
401-1,000	28
1,001-10,000	29

Reports issued using the 95/90 hypergeometric sampling plan shall include some reference to the total number of items submitted in each population, the number fully tested, and a statement related to the statistical significance that can be attached to the analysis.

For example: Item 1 consists of 55 small, clear plastic bags containing a tan powder, and the customer wishes to determine if all bags contain a controlled substance. According to TABLE A: (95/90 sampling plan), if all bags are homogenous, then 19 bags would be chosen at random and fully confirmed.



SOLID DOSE DRUG PROCEDURES

The report would include terminology indicating that 55 bags were submitted, 19 bags were chosen at random and found to contain 'xxx'. Statistical analysis supports that with a 95% level of confidence, at least 90% of the population contains the substance identified.

Table B: (95/50) This sampling plan assures with 95% confidence that at least 50% of the entire population contains the substance identified in the sample

Number of Units	Number sampled
5-12	3
13-66	4
>67	5

Reports issued using the 95/50 hypergeometric sampling plan shall include some reference to the total number of items submitted in each population, the number fully tested, and a statement related to the statistical significance that can be attached to the analysis.

For example: Item 1 consists of 55 small, clear plastic bags containing a tan powder, and the customer wishes to determine if all bags contain a controlled substance. According to TABLE B: (95/50 sampling plan), if all bags are homogenous, then 4 bags would be chosen at random and fully confirmed.

The report would include terminology indicating that 55 bags were submitted, 4 bags were chosen at random and found to contain 'xxx'. Statistical analysis supports that with a 95% level of confidence, at least 50% of the population contains the substance identified.

f. Table C refers to the required sample size to guarantee with 95% confidence that at least 50% or 95% of the population contains controlled substance if it is expected or determined that 1 or 2 sampled units do not contain controlled substances.

Table C: number of samples required to be examined if 1 or 2 units do not contain controlled substance:

Population Size N	50% of Population		90% of Population	
	1 Neg	2 Neg	1 Neg	2 Neg
10	5	5	10	-
11-20	6	8	17	20
21-30	7	9	22	27
31-40	7	9	26	32
41-50	7	10	29	36
51-60	7	10	31	39
61-70	7	10	32	41
71-80	7	10	34	43



SOLID DOSE DRUG PROCEDURES

81-90	7	10	35	45
91-100	7	10	36	46
101-200	8	10	40	53
201-300	8	10	42	55
301-400	8	11	43	57
401-600	8	11	44	58
601-800	8	11	44	59
801-1000	8	11	45	59
1001-5000	8	11	46	61
5001-10000	8	11	46	61

References specific to Sampling

“Part III A – Methods of Analysis/Sampling Seized Drugs for Qualitative Analysis.” Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) Recommendations. 8th ed.; June 13, 2019.

Frank, R.S., Hinkley, S.W. and Hoffman, C.G., Representative Sampling of Drug Seizures in Multiple Containers, Journal of Forensic Sciences, JFSCA, 1991, 36 (2), 350-357.

Coulson S.A., Coxon A., Buckleton J.S., How many Samples from a Drug Seizure Need to be analyzed, Journal of Forensic Sciences, JFSCA, 2001, 46(6), 1456-1461.

2009 UNODC/ENFSI Guidelines on Representative Drug Sampling, European Network of Forensic Science Institutes (ENFSI), 2004, <http://www.ENFSI.org>.

Guidelines on Sampling of Illicit Drugs for Qualitative Analysis, European Network of Forensic Science Institutes (ENFSI), Second Edition, 2016, <http://www.ENFSI.org>.

E2548 Standard Guide for Sampling Seized Drugs for Qualitative and Quantitative Analysis. ASTM International, 2016.

ENFSI DWG Qualitative Sampling Calculator Revision July 2017.xls2007-2016

ENFSI DWG document, DWG-SGL-002 version 001, Hypergeometric Sampling Tool (version 2012) Background of Calculation and Validation, 2012, www.enfsi.eu.

C. IDENTIFICATION REQUIREMENTS

Minimal Requirements for Complete Identification

Category A	Category B	Category C	Cannabis	Category D
-------------------	-------------------	-------------------	-----------------	-------------------



SOLID DOSE DRUG PROCEDURES

			Only	
Mass Spectrometry	Thin Layer Chromatography	Color Tests	Macroscopic Examination	PDR
Infrared Spectrometry	Gas Chromatography	Ultraviolet Spectroscopy	Microscopic Examination	Med. Scan
Raman Spectroscopy	High Performance Liquid Chromatography	Fluorescence Spectroscopy		Poison Control
				Other Reference Material (e.g. Drug Identification Bible, Logo Index, Drugs.com)

1. When a Category A method is used, then at least one other technique (from either Category A, B, C or D) must be used. In the case of a hyphenated method (i.e GC/MS) a third method from Category A, B, C or D must be employed. A technique is considered Category A when the data provides structural information, has a high level of selectivity and is reviewable.

A Category A technique may not be sufficient when:

- The method limits the ability to differentiate the analyte from a structurally similar compound or related compounds
- The state of the sample limits the ability to distinguish the analyte of interest (i.e. mixures or physical condition of the sample)
- The quantity or concentration of the sample is insufficient, and all acceptability criteria are not met

2. When a Category A method is not used, then at least three different methods based on different analytical principles must be employed. Two of the three methods must be from Category B.
3. Cannabis exhibits tend to have characteristics that are visually recognizable. Thus, a macroscopic and/or a microscopic examination of cannabis will be considered as Category B tests when observations include documented details of botanical features. Additional testing must include at least two other techniques from Category A, B, or C. Cannabis cannot be classified as marijuana using the current analytical techniques and would need testing performed by an outside laboratory for marijuana confirmation.



SOLID DOSE DRUG PROCEDURES

- 4. For exhibits of cannabis (e.g. extracts or residues) that lack sufficient observable macroscopic and microscopic botanical detail, D⁹-tetrahydrocannabinol (THC) must be identified utilizing the techniques in Category A and B or A and C.
- 5. For tablet/capsules exhibits, at least one test from Category A and at least one from either Category D or B. Markings on a tablet or capsule will be written in the case notes along with a general description of the tablet/capsule (color, size, etc.). The number or weight of the sample will be written in the case notes.

If the sample cannot be identified by the literature treat the sample the same as an unknown sample and use the customary analytical procedures to identify the drug.

If the sample appears to be altered, counterfeit or homemade, check the contents of the capsule or tablet as above.

NOTE: References for analyses of drugs come from various sources, including the DEA Laboratory Manual, Clarkes' Isolation and Identification of Drugs, and various periodicals

For the use of any method to be considered of value, the test must be considered "positive." While "negative" tests provide useful information for ruling out the presence of a particular drug/drug class, these results have no value toward establishing the forensic identification of a drug substance.

At a minimum, at least one of the methods utilized within the analytical scheme must provide data that is reviewable. Some examples of reviewable data include printed chromatograms, photographs, photocopies of results, or detailed descriptions of morphological characteristics (for cannabis only).

When sample size allows, a minimum of two samplings should be used. A different analytical technique should be applied on the separate sampling for quality assurance purposes. If the sample size is limited, additional measure should be taken to assure that the results correspond to the correct sample.

If a conclusion cannot be drawn based upon the acquired results the sample will be reported as inconclusive and the reason why a conclusion could not be reached must be listed on the Certificate of Analysis.

REPORTING RESULTS:

Results will be phrased with terminology that is clear and precise to the reader of the report (i.e., Customer) Terminology such as:

“ _____ was identified...”

Or



SOLID DOSE DRUG PROCEDURES

“ _____ contain(s)...”

Or

“Quantity insufficient”

Reported results will include the manner of testing, i.e.:

“Method(s) of analysis: _____”

2. Minimal Requirements for Preliminary Identification

- a. General Powders and Residues: At least one positive test from category B or C
- b. Tablets/Capsules: At least one identification from Category D, if possible.

Category B	Category C	Category D 1.
Thin Layer Chromatography	Color Tests	PDR
Gas Chromatography	Ultraviolet Spectroscopy	Med. Scan
Microcrystalline Tests	Fluorescence Spectroscopy	Poison Control
		Other Reference Material (e.g.: Drug Identification Bible, Logo Index, Drugs. com)

REPORTING RESULTS:

Report Tablets/capsules as:

“Description is consistent with _____”



SOLID DOSE DRUG PROCEDURES

Reported results will include the manner of testing, i.e.:

“Method(s) of analysis: _____”

IV. CASE DOCUMENTATION

A. CASE NOTES

The minimum information, which must be contained in the case notes are:

- Laboratory Identification Number
- Start Date
- General Description of Evidence and Packaging
- Condition of packaging (sealed, unsealed)
- Sealed Package Weight (prior to opening container)
- Analyst’s signature/Initials
- Balance used
- Gross Weight (when applicable)
- Net Weight or count (when applicable)
- Sampling date and time (when applicable)
- Reserve Weight or count of material (when applicable)
- Evidence Sampling Plan (Note if less than two aliquots taken from the sample)
- Solvent used
- UoM
- Post Sealed Package Weight (after processing)
- Qualitative Analysis Results
- Summary of Findings
- Date Sealed
- End Date

All case notes, spectra and other data generated during analysis will bear the initials of the analysts and the case number.

B. CASE FILE

The minimal information, which must be contained in the individual case file consists of:

- Copy of the final report/Certificate of Analysis
- Case Review Form (technical/administrative)



SOLID DOSE DRUG PROCEDURES

- Any preliminary, supplementary, or corrected reports
- Solid Dose Drug Worksheet and Case notes
- Evidence Receipt/Contract for Examination form
- Hard copies of data that support the conclusion of the analyst.
- Other: Discrepancy form / correspondence with customer, (if applicable)
- Chain of Custody form

V. GENERAL ANALYTICAL PROCEDURES

NOTE: There are times when deviations from documented policy or procedure is/are necessary. These must be communicated to the customer on the Certificate of Analysis. Refer to the Section's Quality Manual for description and protocols to request deviations.

A. THIN LAYER CHROMATOGRAPHY

NOTE: A Solvent blank and an appropriate control sample(s), (Certified Reference Material) must be run to ensure the system and spray are working correctly. The manufacturer, lot #, and expiration date shall be recorded and included in the case file for CRM's and as well as any other reagents used in the case.

- Place a few milligrams of sample into a numbered disposable test tube.
- Dissolve the sample in an appropriate organic solvent (i.e. methanol).
- Run a thin layer chromatography (TLC) screening test. To a large solvent tank add an appropriate TLC system. Let the system equilibrate for approximately 30 minutes.
- To a TLC plate lightly draw, in pencil, a line approximately 1 inch from one edge of the plate. This is called the origin line.
- Spot an appropriate amount of solvent or unknown from each of the sample tubes along the origin line.
- Spot an appropriate amount of the control(s) on the origin line.
- Place the spotted edge of the plate into the solvent tank and allow the solvent to rise up the plate. As the solvent rises up the plate, the spotted residue from the sample(s) and standard(s) will be carried along with the solvent.
- Before the solvent front reaches the top of the plate, remove plate from tank, mark solvent front, and air dry.
- Air-dry the plate and mark the plate with the analyst's initials and date run.
- Place plate in the UV viewing box and observe the plate under short and long wavelength UV.
- Lightly mark any spots observed under UV light.
- Place plate in fume hood.
- Lightly spray the plate with the appropriate TLC spray.
(See suggested development sequence below)



SOLID DOSE DRUG PROCEDURES

SUGGESTED DEVELOPMENT SEQUENCE FOR GENERAL UNKNOWN POWDER

Iodoplatinate → View with long and short wave UV

- Allow the plate to dry and the colors to develop.
- Compare the color of the spots after spraying and the distance that the sample traveled during development in the solvent compared to the standard.
- Note if the color and the distance the sample traveled matches the standard on the worksheet.
- For a positive TLC result the color of the spots and the distance traveled for the sample will match that of the standard.
- Photograph or photocopy TLC plate and place in case folder.

Criteria for Evaluating Unknowns

For a positive result, the sample will travel the same distance and have the same color as the standard. The solvent blank will yield negative results.

Expected Results

Refer to Clarke, 2nd Edition for color of the appropriate drug.

Systems, Sprays and References

The following system and sprays may be used for TLC.

Systems:

Drug Screen (Davidow)	
Ethyl Acetate	89 ml
Methanol	10 ml
Ammonium Hydroxide	1 ml
B. Davidow, et.al., 'A TLC Screening Test for the Detection of Users of Morphine or Heroin', Amer. Jour. Clin. Path., 46, 58 1966. Also in CRC 'Methodology for Analytical Tox', I. Sunshine.	

Sprays:

Acidified Iodoplatinate Spray (IPT)
Add 25 grams of potassium iodide to a 500 ml volumetric flask
Add 10 ml of concentrated HCL



SOLID DOSE DRUG PROCEDURES

Add 5 ml of 8% platinum chloride

Dilute to 500 ml with distilled water

Clarke, 1st Ed., p.801

B. GAS CHROMATOGRAPHY/MASS SPECTROMETRY

1. SAMPLE PREPARATION

- Add approximately 1 ml of DFTPP internal standard solution to a 2ml GC/MS vial.
- Add sufficient amount of the sample solution to the same GC/MS vial and cap. See VI. Specific Analytical Procedures section for sample solution guidance.
- Repeat for each sample and procedural extraction blank, if applicable.
- Use appropriate method (Rapidrug, WBAMINE2, STER, etc) on the GC/MS.
- A blank (1ml DFTPP internal standard solution and 100 ul of appropriate solvent in a 2 ml GC/MS vial) will be run between each sample and/or standard.

2. Criteria for Evaluating Unknowns

Unknown samples will be evaluated for suitability prior to comparison to known standard. To determine if the unknown sample is suitable for comparison the analyst will evaluate and consider each of the following:

- A) Absence of target compound(s) as listed on the Quant QEdit Report for the method used and/or other compounds at the discretion of the analyst in the blank prior to the sample
- B) Presence of the internal standard peak with a signal to noise ratio > 3:1

If the sample is deemed suitable for comparison the analyst can determine the presence of a controlled substance and/or diluent. To determine the presence of a controlled substance and/or diluent on the GC/MS, the analyst will evaluate and consider each of the following:

- A) Ratios of Target Ion and Qualifying Ions *between the known (standard) and unknown.*
- B) Comparison of the retention times. The sample peak shall be within +/- 0.25 mins. of the reference peak.
- C) Comparison of the unknown spectra to the reference spectra with a minimum quality match of 80 and/or the discretion of the analyst.
- D) Signal to noise ratio >3:1



C. FOURIER TRANSFORM INFRARED SPECTROSCOPY

The following outlines the sample prep and analysis for the Thermo Fisher Nicolet iS20 ATR FTIR.

Launch OMNIC by double-clicking the icon on the desktop. Verify that the “Solid Dose Drug” experiment is selected (visible at the top of the window).

Analyzing Sample Blank

- Move the sample arm to the upright position and turn it to the side. Note: to lower the arm, turn the knob clockwise. To raise the arm, counterclockwise. Should the arm become locked in the up position, meaning you turn the knob and it will not lower, manually move the arm slightly and turn the knob clockwise until the mechanism engages.
- Clean the tray and crystal area by adding solvent to a kimwipe and wiping down the area. AT NO TIME SHOULD CANNED AIR BE USED ON THIS INSTRUMENT IN ANY FORM.
- Click “Col Smp” Button > it will prompt you to enter spectrum title (case and sample number followed by “blank”)
- Click “ok” > it will prompt you to run background
- Click “ok” > to initiate background > click start collection button (upper right corner)
- After background is complete, Click “ok” > lower the arm down until it gently touches the crystal (without sample and w/o locking the arm)
- Click “start collection” > once complete the confirmation box appears > click “YES”
- Save the file by clicking File > Save as > then enter your filename or click the “Set Filename to Title” button. Files shall be saved in the appropriate year folder found in My Documents > OMNIC > Spectra > SDD Analysis
- Evaluate the spectra to ensure it is absent of distinct peaks. If suspected peaks are present, click “Find Pks” button to label peaks. Should some peaks not label, adjust the sensitivity bar on the left of the screen to increase the level and further display peaks.
- Once you are satisfied with the labeling, click the “Replace” button to update your active window. Click “full scale” button to automatically adjust peak heights and labels to fit in the window.
- If there are peaks present that are similar to expected peaks in the sample to be analyzed, perform the cleaning procedure again and analyze a new blank prior to proceeding with sample analysis. Both blanks shall be maintained for the casefile.

Analyzing Samples and Performing Library Search

- Move the sample arm to the upright position and turn it to the side. Note: to lower the arm, turn the knob clockwise. To raise the arm, counterclockwise. Should the arm become locked in the up position, meaning you turn the knob and it will not lower, manually move the arm slightly and turn the knob clockwise until the mechanism engages.
- Clean the tray and crystal area by adding solvent to a kimwipe and wiping down the area. AT NO TIME SHOULD CANNED AIR BE USED ON THIS INSTRUMENT IN ANY FORM.
- Click “Col Smp” Button > it will prompt you to enter spectrum title (case and sample number)
- Click “ok” > it will prompt you to run background
- Click “ok” > to initiate background > click start collection button
- After background is complete > Click “ok”



SOLID DOSE DRUG PROCEDURES

- Add a small amount of sample to the crystal and lower the arm down until it locks in place
- Click “start collection” > once complete the confirmation box appears > click “YES”
- Click “Find Pks” button to label peaks. Should some peaks not label, there is a sensitivity bar on the left of the screen that can be increased to further display peaks.
- Once you are satisfied with the labeling, click the “Replace” button to update your active window. Click “full scale” button to automatically adjust peak heights and labels to fit in the window.
- Save the file by clicking File > Save as > then enter your filename or click the “Set Filename to Title” button.
- With both the blank and appropriate sample still open, click the “Stack Spe” button from the toolbar.
- With the sample selected (spectra line will be red if it is the active selection) click “Search” button > the library search should open up with the appropriate hits for the libraries selected
- Click on the appropriate match > click “Overlay” button down below
- If satisfied click “window” on the top menu and select the window with the current sample and blank displayed. (Window 1/Window 2/etc...).
- Once the correct window is displayed showing the current blank and sample, click “report” in the top menu.
- Click print/preview to load the SDD Report Template and view the preview.
- Ensure the correct data is displayed and the correct library match is loaded.
- Click Print
- If an acceptable library match has not been achieved, close the search window and perform a subtraction as outlined below.

Should a zoom be required the traditional right-click and drag can be used or you can use the spectra window at the bottom of the screen to adjust what portion of the spectra is visible. To reset the zoom to the previous setting there are two easy ways of doing so. 1) double left-click in the white portion (the selected portion) of the spectra window at the very bottom or 2) select the View menu and select “Undo Limit Change”

The libraries approved for casework comparisons are:

- SDD Library
- Master SFL1 FTIR library v. 082719
- HR Georgia State Forensic Drugs

Performing Subtraction:

Should a low quality match be attained on a specific sample, an analyst can subtract a known reference spectra from an approved library to improve the unknown spectra.

- Ensure sample spectra is open
- Open the reference spectra to subtract
 - Click the “Lib Mgr” button on the toolbar. Select the desired search library (or use the search spectra function). Select the desired compound. Click the “Add to Window” button. Scroll down the list of windows to add the spectra to the target window and click the “Add” button.



SOLID DOSE DRUG PROCEDURES

- Click on your unknown spectra (should have a red border) and then also select the spectra to subtract by holding the Ctrl button while selecting the second spectra (both should have a red border)
- Go to Process > Subtract
- Click the "Add" button in the upper right corner to add the new spectra to a new window.
- Click "Search" button > the library search should open up with the appropriate hits for the libraries selected
- Click on the appropriate match > click "Overlay" button down below
- Click "window" on the top menu and select the window with the current sample and blank displayed. (Window 1/Window 2/etc...).
- Once the correct window is displayed showing the current blank and sample, click "report" in the top menu.
- Click print/preview to load the SDD Report Template and view the preview.
- Ensure the correct data is displayed and the correct library match is loaded.
- Click Print
- Save the subtraction file by clicking File > Save as > then enter your filename or click the "Set Filename to Title" button and add subtraction to the end of the filename.

Criteria for Evaluating Unknowns

Unknown samples will be evaluated for suitability, prior to comparison to known standard, by evaluation of the blank and the sample. The maximum scan range permitted is 4,000-400 wavenumbers, however this can be adjusted to narrower range to remove excessive noise peaks in the lower wavenumber region, as long as all required peaks for the compound in the tables listed below are still present in the spectra.

To determine if the unknown sample is suitable for comparison the analyst will evaluate and consider each of the following:

- A) Ensure the blank was run using a resolution of 4 and run at 16 scans. Evaluate the blank run prior to evaluation of the sample to ensure the blank is clean and free of any obvious interference and/or background noise. A clean blank is defined as a blank run with the same scan range as the sample and having all peaks beyond the noise region having a response below 0.05, or if there are peaks present above 0.05 the peaks will be labeled and no peaks of interest will be present. If the blank is deemed suitable, move on to evaluation of the sample.
- B) Evaluate the overall appearance of the sample spectra and ensure it is free of any obvious interference and/or background noise. Ensure the sample was run using a resolution of 4 and run at 16 scans.

If the sample is deemed suitable for comparison the analyst can determine the presence of a controlled substance and/or diluent. To determine the presence of a controlled substance and/or diluent on the FTIR the analyst will evaluate and consider each of the following:



SOLID DOSE DRUG PROCEDURES

A) Overlay and compare with the reference spectra and achieve a library match to an approved library of 80 or greater.

B) At least 5 significant peaks that help to identify the compound should agree within +/- 4 cm-1 of known reference peaks. Significant peaks for commonly encountered drugs are listed below and shall be used for comparison. All peaks must be present within the unknown sample before it is deemed 'confirmed' by FTIR.

Cocaine Base	
Peak Number	Peak at Wavenumber cm-1
1	712
2	1106
3	1036
4	1275
5	1450
6	1706
7	1734

Cocaine Hydrochloride	
Peak Number	Peak at Wavenumber cm-1
1	730
2	1105
3	1230
4	1265
5	1712
6	1728

Methamphetamine Hydrochloride	
Peak Number	Peak at Wavenumber cm-1
1	698
2	747
3	1059
4	1453
5	1486
6	1603

Amphetamine	
Peak Number	Peak at Wavenumber cm-1
1	696
2	738
3	1454
4	1496
5	1513
6	1573



SOLID DOSE DRUG PROCEDURES

Pseudoephedrine	
Peak Number	Peak at Wavenumber cm-1
1	543
2	630
3	700
4	1006
5	1373
6	1454

Ephedrine	
Peak Number	Peak at Wavenumber cm-1
1	671
2	697
3	750
4	991
5	1388
6	1453

Phentermine	
Peak Number	Peak at Wavenumber cm-1
1	447
2	702
3	727
4	1284
5	1389
6	1610

α-PVP	
Peak Number	Peak at Wavenumber cm-1
1	718
2	770
3	1232
4	1337
5	1449
6	1681

For drugs other than those listed above, confirmation criteria shall include a library match score of 80 or greater to the HETL library, created in house using reference material purchased from an approved vendor, and at least five prominent peaks within +/- 4 cm⁻¹ are present when compared with a publish reference spectra from SWGDRG, Cayman Chemical, Cerilliant, or other similar source.

Adding Compounds to the SDD Library



SOLID DOSE DRUG PROCEDURES

With the spectra selected, click “Add Lib” button on the toolbar. A window will open, select the “HETL SDD” library and click “OK”. In the next window, enter the requested information for the spectra (Name, Manufacturer, Lot, Exp) and then click “OK”.

Deleting Compounds to the SDD Library

Click the “Lib Mgr” button on the toolbar. Select the “HETL SDD” library from the search libraries. Select the spectra to be deleted and click the “Delete” button. The compound name will still be visible in the index and an “X” will be displayed in the delete column.

VI. SPECIFIC ANALYTICAL PROCEDURES

A. Cannabis/Hashish

Chemicals:

SDD Solvent Mix
Chloroform
6N HCL

Safety Precautions and PPE:

Lab coats, gloves and eye protection will be worn when handling chemicals in accordance with the SDS.

Use respiratory protection when handling moldy samples.

ANALYSIS:

1. Weight/Count

Obtain the total net weight of the plant/resinous material or total count of whole plants and note the weight/count in case notes. Report all weights as net weights in grams (or pounds) on worksheet and report/Certificate of Analysis.

2. Microscopic

The identification of cannabis depends largely on identifying its botanical features. Cannabis is characterized by the presence of cystolithic, glandular and non-glandular hairs on the leaf.

A. Cystolithic Hairs

Cystolithic hairs are claw-shaped, usually curved structures with a broad circular base and are mostly one-celled. Within the hair is a cystolith of calcium carbonate. The presence of a true cystolith should be confirmed by the addition of hydrochloric acid.



SOLID DOSE DRUG PROCEDURES



- Place a small amount of plant material on a glass slide.
- Add a few drops of water and cover with a coverslip.
- Add a few drops of 6 N Hydrochloric Acid to the side of the coverslip.
- Evolution of bubbles of carbon dioxide confirms the presence of a true cystolith.


B. Glandular Hairs

Glandular hairs are important because they contain and secrete resin. They are short and may be either unicellular or multicellular. The bigger glandular hairs have a multicellular stalk with heads containing 8 to 16 cells.



C. Non-glandular Hairs

On the reverse side of the leaf containing the cystolithic hairs can be found numerous long, wide nonglandular covering hairs.



A positive microscopic exam will include the observation/presence of **all three types** of hairs.

- Examine the plant material under microscope.
- Look for presence of the botanical features (hairs), indicative of Cannabis and record in the case notes.

3. Extraction for GC/MS

- To a small amount of dried plant material in a dish or test tube add approximately 2-5 SDD Solvent Mix. The resin from the plant, which contains THC and other Cannabinoids, will be suspended in the solvent.



SOLID DOSE DRUG PROCEDURES

- Shake the tube and let sit for approximately one minute.
- Retain 100-200ul of the solvent in a new test tube for GC/MS
 - If necessary, concentrate the sample by placing the test tube under N₂ gas to evaporate a portion of solvent. Ensure a similarly prepared blank is also prepared, dried down with the sample and run in conjunction with the sample.

4. Gas Chromatography/Mass Spectrometry

Use a portion of the retained liquid in the test tube for a gas chromatography/mass spectrometry (GC/MS) confirmation analysis.

- For solvent blank: Fill GC/MS vial with approximately 1mL of appropriate solvent and add 25ug of TPP or DFTPP Internal Standard.
- For Sample: Fill GC/MS vial with approximately 1mL of appropriate solvent and add 25ug of TPP or DFTPP Internal Standard. Add appropriate volume of sample dependent upon concentration.
- Run all samples on THC, Rapid Drug or Steroid method on GC/MS to determine the presence of Delta-9 THC.

5. Reporting

The laboratory currently does not perform quantitation of delta-9 THC and CBD to differentiate marijuana from hemp. As such, if the sample includes a positive microscopic identification and confirmation of delta-9 THC the report shall state: "Plant like material identified as cannabis and contains delta-9 THC. Further analysis would be required to differentiate the material as marijuana or hemp."

B. General Powders/Residues

Chemicals:

TLC Solvent System - Refer to Thin Layer Chromatography Section for chemicals

TLC Spray – Refer to Thin Layer Chromatography Section for chemicals

Hexanes	Acetonitrile	9.5 pH Ammonium Buffer	Isopropanol
Chloroform	Ethyl Acetate	Methanol	Acetone
DFTPP	95% Ethanol		Methylene Chloride

Safety Precautions and PPE:

Lab coats, gloves and eye protection will be worn when handling chemicals in accordance with the SDS.



SOLID DOSE DRUG PROCEDURES

When handling hypodermic apparatuses, the analyst will remove caps employing mechanical means such as tweezers. Once removed, the caps will not be replaced back on the hypodermic apparatus. Instead, place cap and needle back into the submitted biohazard container.

ANALYSIS:

1. Weight

Obtain the total net weight of the material and note the weight in case notes. Report all weights as net weights on worksheet and Report/Certificate of Analysis.

2. Sample Prep and Extraction

Powders:

When applicable, two aliquots will be taken for separate tests. Powders will be dissolved in SDD Mix A/B/C, methanol, or another appropriate solvent depending on suspected substance (consult the Merck Index, Clarke's Isolation and Identification of Drugs, or other appropriate reference for solubility and chemical property information). A portion of the dissolved sample can then be used for TLC or GC-MS analysis. A separate portion of the powder can be used for FTIR analysis. For powders which contain mixtures, either liquid-liquid extraction using water and an appropriate immiscible solvent, or an acidic/ basic extraction can be used (refer to tablet/capsule section of this SOP for possible extraction examples or consult the above listed references). When multisolvent (complex) extractions are performed an extraction procedure blank will be utilized. An extraction procedure blank sample shall be run as an extraction blank alongside samples following the same procedure listed below. All extraction procedure blanks, and sample data will be included in the casefile.

Residues:

Residual samples where no weighable amount of sample is present should be noted in the case notes. The sample/item which contains the residue can either be rinsed or swabbed with SDD Mix A/B/C, methanol, or an appropriate solvent and that sample used for GC-MS and TLC analysis. If the residue contains a mixture the sample can be rinsed/swabbed with water and either a liquid-liquid, acidic, or basic extraction used.

3. Thin Layer Chromatography – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part A)

NOTE: An appropriate control sample(s) (e.g. Cocaine standard) must be run to ensure the system and spray are working properly.

- Compare the color of the spots after spraying and the distance that the sample traveled during development in the solvent compared to the standard.



SOLID DOSE DRUG PROCEDURES

- Note if the color and the distance the sample traveled matches the standard on the worksheet.
- For a positive TLC result the color of the spots and the distance traveled for the sample will match that of the standard.
- Photograph or photocopy TLC plate and place in case folder.

4. Gas Chromatography/Mass Spectrometry – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part B)

Use a portion of the remaining extracted sample in the test tube for a gas Chromatography/Mass Spectrometry (GC/MS) confirmation analysis.

- Add approximately 1 ml of DFTPP internal standard solution to a 2 ml GC/MS vial.
- Add sufficient amount of sample (varying on suspected concentration of drug being tested) from the test tube to the same GC/MS vial and cap.
- Repeat for each sample and procedure blank, if applicable.
- Prepare a blank (1ml DFTPP internal standard solution and 100ul appropriate solvent) to be run between each sample.
- Run GC/MS analysis using the appropriate method (Rapidrug, WBAMINE2, STEROID).

5. FTIR

Use a separate aliquot, if possible, for FTIR confirmation analysis.

Refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part C for analysis by Fourier Transform Infrared Spectroscopy.

C. TABLETS/CAPSULES/FILMS

Chemicals:

TLC Solvent System - Refer to Thin Layer Chromatography Section for chemicals

TLC Spray – Refer to Thin Layer Chromatography Section for chemicals

Hexanes	Isopropanol	Methanol	NaOH
DFTPP	Methylene Chloride	95% Ethanol	Acetone
Acetonitrile	Ethyl Acetate	NH ₄ OH	Chloroform



SOLID DOSE DRUG PROCEDURES

Safety Precautions and PPE:

Lab coats, gloves, and eye protection will be worn when handling chemicals in accordance with the SDS.

ANALYSIS:

1. Weight/Count

Obtain the total count of the tablets/capsules/Films and record in case notes. Obtain the net weight of at least one item and record it in the case notes.

2. Extraction

Extraction A Low Concentration Prescriptions Lisdexamfetamine	Extraction B
<ol style="list-style-type: none"> 1. Crush tablets(s), empty capsule, or sample strip and place portion of sample in a test tube. Repeat for each sample being tested. 2. Prepare extraction procedure blank 3. Perform an acidic/basic/neutral extraction on extraction procedure blank and all samples in extraction set <p>IF NECESSARY:</p> <ol style="list-style-type: none"> 4. Dry down sample and procedure blank 5. Place appropriate amount of solvent and internal standard into a GC/MS vial and cap for procedure blank and each sample 6. Run GC/MS analysis 	<ol style="list-style-type: none"> 1. Crush tablet(s) and place in a test tube. 2. Add methanol or appropriate solvent (use portion for TLC) 3. Transfer portion of solvent into a GC/MS vial with internal standard and cap/crimp

3. Thin Layer Chromatography – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part A)

NOTE: An appropriate control sample(s) (e.g. Cocaine standard) must be run to ensure the system and spray are working properly. Record manufacturer, lot #, and expiration date on TLC forms/worksheet.

- Compare the color of the spots after spraying and the distance that the sample traveled during development in the solvent compared to the standard.
- Note if the color and the distance the sample traveled matches the standard on the worksheet.
- For a positive TLC result the color of the spots and the distance traveled for the sample will match that of the standard.
- Photograph or photocopy TLC plate and place in case folder.



SOLID DOSE DRUG PROCEDURES

4. Gas Chromatography/Mass Spectrometry – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part B)

Use a portion of the remaining sample in the test tube for a gas chromatography/mass spectrometry (GC/MS) confirmation analysis.

- Add approximately 1 ml of DFTPP internal standard solution to a 2 ml GC/MS vial.
- Add sufficient amount of sample (varying on suspected concentration of drug being tested) from the test tube to the same GC/MS vial and cap.
- Repeat for each sample and procedure blank, if applicable.
- Prepare a blank (1ml DFTPP internal standard solution) to be run between each sample and 100ul of appropriate solvent
- Run GC/MS analysis using the appropriate method (Rapidrug, WBAMINE2, STER, RapidSuboxone, etc).

5. FTIR (If necessary) – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part C)

Use a portion of the remaining sample in the test tube for FTIR confirmation analysis.

- Dry the sample on a watch glass
- Purify sample (crystals) by extracting with appropriate solvent(s) and drying.
- Place sample on appropriate glass slide and place on microscope.
- Run FTIR analysis (Refer to Section IV. GENERAL ANALYTICAL PROCEDURES – Part D for analysis by Fourier Transform Infrared Spectroscopy)

D. SUSPECTED LSD

Samples suspected of containing lysergic acid diethylamide (or lysergic acid methylpropylamide) need to be handled carefully when being analyzed. LSD will most often be placed on paper, small gelatin squares, and very small homemade tablets or in a liquid.

Chemicals:

TLC Solvent System (9:1Chloroform:Methanol) - Refer to Thin Layer Chromatography Section for chemicals

TLC Spray (Van Urks [Erlisch's]) – Refer to Thin Layer Chromatography Section for chemicals

Concentrated HCL Methanol Chloroform DFTPP Ethanol p-dimethylaminobenzaldehyde

Safety Precautions and PPE:

Lab coats, gloves, and eye protection will be worn when handling chemicals in accordance with SDS.



SOLID DOSE DRUG PROCEDURES

ANALYSIS:

1. Weight/Count

Obtain the total number of dosage units (perforated squares on paper, number of gelatin squares, etc.). The number of dosage units will be reported as such on the final report/Certificate of Analysis.

2. Extraction

- After determining the number of dosage units, prepare for the analysis of the sample by placing an appropriate number of dosage units in a disposable glass test tube.
- Cover the carrier with 1-2 ml of methanol and let stand for approximately fifteen minutes.
- While the LSD is being extracted into the methanol, check the liquid in the test tube for fluorescence in the viewing box while using the long wave UV lamp. Fluorescence is indicative of LSD and/or LAMPA.

3. Thin Layer chromatography - (used as an initial screening test for LSD) - (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part A)

- Add a mixture of 9 ml chloroform to 1ml of methanol in a solvent tank and let equilibrate.
- On a silica gel TLC plate, lightly draw a line approximately one centimeter from the end of the plate. (This is the origin line).
- Spot the extracted sample in the center of the origin line.
- Spot an LSD standard and a LAMPA standard on the origin line.
- Place the TLC plate in the solvent tank
- When the solvent front has reached the upper end of the plate, remove it from the solvent tank and lightly mark the solvent front with a pencil.
- Dry the plate and mark with the analyst's initials and date run. Look at the dried plate in the viewing box under long wave UV light. The LSD spots should appear as small fluorescent spots. Lightly mark these spots with a pencil.
- In the spray box in the hood, lightly spray the plate with p-dimethylaminobenzaldehyde (Erich's) LSD spray. The LSD spots on the TLC plate will turn purple after spraying. A second or third spraying might be necessary. Warming the plate by warm air will help hasten color development.
- Allow the plate to stand for 15 minutes.



SOLID DOSE DRUG PROCEDURES

- Compare the color of the spots after spraying and the distance that the sample traveled during development in the solvent compared to the standard.
- Note if the color and the distance the sample traveled matches the standard on the worksheet.
- For a positive TLC result the color of the spots and the distance traveled for the sample will match that of the standard.
- Photograph or photocopy TLC plate and place in case folder.

4. Gas Chromatography/Mass Spectrometry – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part B)

Use a portion of the remaining sample in the test tube for a gas chromatography/mass spectrometry (GC/MS) confirmation analysis.

- Add approximately 1 ml of DFTPP internal standard solution to a 2 ml GC/MS vial.
- Add sufficient amount of sample (varying on suspected concentration of drug being tested) from the test tube to the same GC/MS vial and cap.
- Repeat for each sample and procedure blank, if applicable.
- Prepare a blank (1ml DFTPP internal standard solution) to be run between each sample and 100ul appropriate solvent.
- Prepare LSD or LAMPA standard by adding 10µl of a CRM to 100-300 µl SDD Mix C in an insert.
- Run both standard and sample by GC/MS analysis using the LSD method

E. PSILOCYBE MUSHROOM

Psilocybe mushrooms are relatively small mushrooms that contain the hallucinogenic compounds psilocin and psilocybin. This is a complex biological matrix, requiring extraction prior to analysis.

NOTE: If the mushroom samples are fresh, they must first be dried in the 105° C oven for approximately 15-30 minutes.

Chemicals:

TLC Solvent System - Refer to Thin Layer Chromatography Section for chemicals

TLC Spray – Refer to Thin Layer Chromatography Section for chemicals

6% Glacial Acetic Acid Dichloromethane Ammonium Hydroxide Chloroform

Safety Precautions and PPE:

Lab coats and eye protection will be worn when handling chemicals in accordance with the SDS.



SOLID DOSE DRUG PROCEDURES

ANALYSIS:

1. Weight

Obtain the total net weight of the material and note the weight in case notes.

2. Extraction Option 1

Note an extraction procedure blank sample shall be run as an extraction blank alongside samples following the same procedure listed below. All extraction procedure blanks, and sample data will be included in the casefile.

- Prepare a 6% by volume glacial acetic acid solution
- Weigh out approx. 2.0 grams of mushrooms
- Break-up the dried mushrooms into smaller pieces
- Place the mushroom pieces into a dish or beaker and add the 6% acetic acid solution – add enough acetic acid to completely cover the small pieces
- Let stand for at least 30 minutes, stirring occasionally
- Filter out the mushroom pieces and retain the liquid portion
- Transfer the liquid portion into a separatory funnel
- Wash the contents of the separatory funnel with dichloromethane. Vigorously invert the funnel to mix the solvent and aqueous layer. Allow sample to sit for a few minutes and settle into two layers. Drain off the lower organic layer.
- Repeat the washing of the aqueous layer two more times with dichloromethane
- Check the pH of the aqueous layer – should be between pH 1 and 2
- Basify the solution with ammonium hydroxide until you reach pH between 9 and 10
- Wash the solution with chloroform, vigorously inverting the separatory funnel to mix the two layers. Be sure to vent the separatory funnel. Allow the sample to sit for approximately 10 minutes. Drain and save the chloroform layer (psilocin is in the chloroform layer) into an evaporating dish. If necessary, filter the chloroform layer.
- Repeat chloroform wash two more times – combining the chloroform layers into the same evaporating dish.
- If TLC analysis is to be performed, reserve a portion of the chloroform solution. If necessary, concentrate the sample by placing under N₂ gas.
- Evaporate the remaining chloroform to dryness, filter (if necessary) and use the residue for GC/MS analysis

Extraction Option 2

Sampling

Fill two test tubes with approximately half an inch (thumb width) of broken mushroom material, ensuring a good representative sample. These samples will be used for the rapid screen method. Additionally, add approximately two grams of material to an appropriate vessel to be used for the extraction, should it be required for analysis.

Rapid Screen Method:



SOLID DOSE DRUG PROCEDURES

Individual sample prep: Add SDD mix A/B/C to one of the test tubes until the solvent is just covering the material. Vortex the test tube appropriately and allow to soak. It is recommended to allow the material to soak for at least one hour. Longer soak times are more likely to present higher concentration of any analytes present in the material.

3. GC/MS Confirmation - (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part B)

Extraction Option 1:

Use a portion of the remaining sample in the evaporation dish for a gas chromatography/mass spectrometry (GC/MS) confirmation analysis.

- Add 100-200ul of MeCL₂/EtOH/DFTPP solution to the residue in the evaporation dish
- Transfer extract to a GC/MS vial with an insert and cap.
- Repeat for each sample and procedure blank, if applicable.
- Prepare a blank (DFTPP internal standard solution and appropriate solvent) that matches the preparation of the sample (insert/no insert/concentrated/etc..) and ensure the solvent concentrations is the same, or more concentrated, than the sample, to be run between each sample.
- Run GC/MS analysis using the appropriate method (Rapidrug).

Extraction Option 2:

- Prepare a GC/MS vial for analysis by adding a portion of the sample solvent to vial and then adding the appropriate amount of SDD mix A/B/C.
 - recommended preparation: in an insert, place 20 to 50 microliters of sample solvent and 100 to 150 microliters of SDD mix A/B/C).
- Prepare a blank similarly to the sample, ensuring that a volume of the same solvent used for the sample preparation, from the same source vessel used, that meets or exceeds the volume of sample solvent that was added to the GC/MS vial.
- The blank should be run, followed by the sample, using an approved method on the GC/MS (RAPIDRUG/STER). If a psilocin is not confirmed via the rapid screen method, extraction method 1 should be performed.

4. Thin Layer Chromatography - (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part A)

For suspected psilocybe mushrooms –

- Use Drug Screen (Davidow) system for screening. Spot extract and standard psilocin on TLC plate and develop in large tank. After development in tank, dry the plate and mark with the analyst's initials and date run. Inspect the plate in a view box with short wave UV lamp. Mark spots that correspond with psilocin standard. Spray with acidified iodoplatinate reagent to visualize spots.



SOLID DOSE DRUG PROCEDURES

- Compare the color of the spots after spraying and the distance that the sample traveled during development in the solvent compared to the standard.
- Note if the color and the distance the sample traveled matches the standard on the worksheet.
- For a positive TLC result the color of the spots and the distance traveled for the sample will match that of the standard.
- Photograph or photocopy TLC plate and place in case folder.

5. Microscopic Examination

For food products suspected of containing psilocybe mushrooms and cannabis/delta-9 THC microscopic examination may be necessary to assist in the analysis.

F. LIQUID SAMPLES AND FOOD PRODUCTS

Chemicals:

TLC Solvent System - Refer to Thin Layer Chromatography Section for chemicals

TLC Spray – Refer to Thin Layer Chromatography Section for chemicals

Chloroform

Methylene Chloride

Isopropanol

Sodium Hydroxide

Ammonium Hydroxide

Concentrated HCL

6N HCL

Safety Precautions and PPE:

Lab coats, gloves, and eye protection will be worn when handling chemicals in accordance with the SDS.

ANALYSIS:

1. Volume

Estimate the total volume of the liquid, if possible, and note in case notes.

2. Extraction

Aqueous liquid samples can be extracted with an acidic, basic and/or neutral system using an appropriate immiscible solvent depending on the suspected or purported target analyte(s). When multisolvent (complex) extractions are performed an extraction procedure blank will be utilized.



SOLID DOSE DRUG PROCEDURES

An extraction procedure blank sample shall be run as an extraction blank alongside samples following the same procedure listed below. All extraction procedure blanks, and sample data will be included in the casefile.

Solid food samples can be soaked in water and the water portion then treated as a liquid sample above. Suspected $\Delta 9$ THC food products can be soaked in –SDD Mix solution. Consult the Merck Index, Clarke's Isolation and Identification of Drugs, or other appropriate reference for solubility and chemical property information.

3. Thin Layer Chromatography – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part A)

NOTE: An appropriate control sample(s) (e.g. Cocaine standard) must be run to ensure the system and spray are working properly.

- Note the color of the spots after spraying and the distance that the sample traveled during development in the solvent compared to the standard.
- Compare the color of the spots after spraying and the distance that the sample traveled during development in the solvent compared to the standard.
- For a positive TLC result the color of the spots and the distance traveled for the sample will match that of the standard.
- Photograph or photocopy TLC plate and place in case folder.

4. Gas Chromatography/Mass Spectrometry – (refer to Section V. GENERAL ANALYTICAL PROCEDURES – Part B)

Use a portion of the remaining sample in the test tube for a gas chromatography/mass spectrometry (GC/MS) confirmation analysis.

- Add approximately 1 ml of DFTPP internal standard solution to a 2 ml GC/MS vial.
- Add sufficient amount of sample (varying on suspected concentration of drug being tested) from test tube to the same GC/MS vial and cap.
- Repeat for each sample and procedure blank, if applicable.
- Prepare a blank (1ml DFTPP internal standard solution and 100ul of appropriate solvent) to be run between each sample.

Run GC/MS analysis using the appropriate method (Rapidrug, WBAMINE2, STER, etc) on the mass spectrometer.



G. WASTE

1. Waste Stream Evaluations

- All procedures and processes involving hazardous chemical, biological or drug waste must have a waste stream evaluation form completed and on file with the Quality Manager prior to performing the procedure.
- All new chemicals/procedures must be evaluated prior to purchase to ensure an appropriate waste stream is available for disposal. See the Chemical Hygiene Plan for more the New Chemical Procurement procedure.

2. Hazardous Solvent Waste

- All extraction waste for evaluated procedures shall be collected in the Forensic liquid dual waste satellite waste container. See the Chemical Hygiene Plan and RCRA Plan for specifics relating to satellite waste containers.
- Biological waste shall be collected in the Forensic liquid dual waste satellite waste container.

3. GC/MS Vial Waste

- All GC/MS vials used to analyze seized drug evidence using evaluated procedures shall be collected in the Forensic GC/MS Vial satellite waste container. See the Chemical Hygiene Plan and RCRA Plan for specifics relating to satellite waste containers.

4. Residual Evidence Waste

- All residual waste from processing of seized drug evidence will be collected in the Rx Destroyer, or similar product, collection container. Residual evidence waste collected in the container are rendered inactive and irretrievable and may be disposed of in the regular trash or removed by an approved waste hauler.

5. Consumables used to process seized drug evidence

- Any lab consumables used to process seized drug evidence shall be disposed of in a glass waste box that is marked for MDEA disposal.
- Full MDEA glass boxes should be sealed with evidence tape and stored in the evidence suite for pick up and incineration by MDEA.

6. Reference Materials

- Any DEA non-exempt reference material must be disposed of following the procedure outline in the SOP Manual.
- Expired DEA exempt reference materials that are not empty shall be disposed of in the Forensic GC/MS vial waste satellite waste container.
- Empty DEA exempt reference material containers shall be disposed of in a glass waste box. Please reference the definition of empty found in the Chemical Hygiene and RCRA plan.



SOLID DOSE DRUG PROCEDURES

APPENDIX A

OPERATION OF THE GC-MS



GAS CHROMATOGRAPHY - MASS SPECTROMETRY

1. INSTRUMENT PREPARATION

The following is not meant to replace the manuals supplied by the instrument vendor, but rather to provide a general 'step by step' overview to the operation of the GCMS. In no way is this meant to be a detailed procedure that must be fully followed and documented in the exact order. Rather it is designed to be a resource, or 'quick reference guide' to any new employee learning MS and specifically the system currently in use at HETL.

Fill solvent wash bottles on the auto-sampler tower. There are two bottles: one for methylene chloride and one for methanol.

Tune the mass spectrometer. On the instrument control panel, click the "Tune MS icon" (tuning fork and music notes picture). Evaluate the generated tune and determine if the tune is satisfactory.

Make sure printer has paper in the paper tray.

Check the pressure of the Helium carrier gas tank. (Change out the Helium tank when the pressure is down to 500 psi. **DO NOT** drain the tank dry).

2. PREPARE THE SEQUENCE

Arrange vials in the auto-sampler tray(s).

Begin by clicking the "Write Sequence Icon" (Pencil and 3 auto-sampler vials picture) on the Instrument Control Panel.

Click the "Data Path" box at the top of the screen.

The data path designation is the following:

D:\HPCHEM\2\DATA\MMDDYY

MMDDYY is the six-digit date designation representing the day the sequence was started.

In the case that more than one sequence is run on the same date add the suffix "A".

(Example: MMDDYYA)

Continue onto the next letter of the alphabet for each subsequent sequence begun on that day.

To add a date to the list of data folders, highlight the "2" in the menu and click the box "Make New Folder".



SOLID DOSE DRUG PROCEDURES

Fill in the Sample Log Table using the following table as a template.

Type	Vial	Data File	Method	Sample	Multiplier	Comment
SAMPLE	Begin with first vial no.	Begin with 001	RAPIDRUG STER WBAMINE2 Etc.	BLANK, CASE/ SAMPLE NO., STANDARD	1.0000 or Calculated value for quantitation	Lot No.

Complete a row for each vial on the auto-sampler. Use the highlight and right click features for cutting, pasting, copying, and repeating row function.

When the Sample Log Table is complete, CLICK OK.

Click the “Save Sequence Icon” (3 ¼ inch Floppy Disk and 3 auto-sampler vials picture). Save the sequence with the six-digit date designation matching the data path designation. (Example: MMDDYY.S)

Click the “Check Sequence Icon” (Red Check mark and 3 auto-sampler vials picture). Make sure the box next to the statement “Overwrite Existing Data Files” is NOT checked. Click OK and view the sequence. Double check the vial numbers, data path designation and sequence file name. Printing this document is optional.

Again, click the “Save Sequence Icon” (3 ¼ inch Floppy Disk and 3 auto-sampler vials picture).

3. RUN SEQUENCE-DATA ACQUISITION

Click the “Run Sequence Icon” (Yellow stick figure in the running position and 3 auto-sampler vials picture). This will start the instrument injecting samples. Watch the first sample injection to ensure the auto-sampler is functioning properly.

4. DATA ANALYSIS

- CLICK – Save Method (if different from method being sought)
- CLICK – Load Method
- CLICK - Load Data File
- CLICK - Quantitate
- CLICK – Calculate
- CLICK – View
- CLICK- QEDIT QUANT RESULTS
- Go to DFTPP – CLICK
- Review responses, ions, and RT
- Go to Suspected Drug(s) – CLICK
- Review responses, ions, and RT
- Perform background subtraction if necessary



SOLID DOSE DRUG PROCEDURES

QDel any non-matching compounds

COMPARE Q SPECTRA WITH LIBRARY SPECTRA

CLICK – Spectrum

Perform background subtraction if necessary

CLICK – Display Reference Spectra

Review responses, ions, and RT of Sample spectrum (top) and Reference spectrum (bottom)

NOTE: The retention times for standards (reference spectra) and unknowns will be within +/- 0.25 minutes. Library matches for confirmations should be made to the HETLSDD Library, if possible. Other approved available reference libraries can also be used, if necessary.

CLICK - Qedit

CLICK – Graphics Report to the Printer

Exit (close QEDIT QUANT RESULTS window)

SAVE changes to Quantitation Results? CLICK – YES

S/N Report

When a S/N ratio >3:1 is not clearly evident from the Quant QEdit report a S/N report using the target ion for the compound in question may be generated and included in the file.

PRINT FINAL REPORT

CLICK – Quantitate

CLICK – Generate Report

Under “Quant Report Options”: Style-**Summary**; Destination-**Printer**

CLICK - OK

TO PRINT TOTAL SCAN AND SPECIFIC SPECTRA

CHOOSE Peak of interest

Left CLICK on the peak

(Double right CLICK on the Mass Spectrum for library search report)

Go to File Menu

Select Print

Select Print Trace and Spectrum

CLICK – OK

5. GC-MS PROGRAMS (list not inclusive)

WBAMINE2

STER

RAPIDRUG

LSD

RAPIDSUBOXONE

THC



Maintenance of GC/MS

Weekly Maintenance

- Change liner, septum, and o-ring
- Clean syringe
- Run Air and Water check
- Run QC Check solution
 - QC Check solution will consist of a set mixture of at least three standards and DFTTP internal standard. The same mixture will be run every week and after any additional instrument maintenance or repairs.
 - Data will be entered into a tracking spreadsheet and monitored to evaluate instrument performance
- Check diffusion pump fluid level

Monthly Maintenance

- Copy all case work and methods data from the previous month and transfer it to the appropriately labeled folder on the external hard drive
- Run the computer defragment software
- Restart Computer

As Needed Maintenance

- Clean source and Auto-tune
- Change gold seal
- Change air tank
- Change gas traps and purifiers
- Replace/trim column
- Lubricate Seals

Every 6 Months

- Check calibration vial
- Replace foreline pump oil

Every 12 Months - Performed during PM, when possible

- Replace traps and filters
- Replace diffusion pump fluid



SOLID DOSE DRUG PROCEDURES

APPENDIX B

OPERATION OF THE FTIR



SOLID DOSE DRUG PROCEDURES

5. FT-IR MAINTENANCE

WEEKLY MAINTENANCE – Perform in the below order

- LASER ALIGNMENT AND VERIFICATION

Laser alignment and verification shall be performed at least once per week. To perform the test, click on the Experiment Setup button on the far left of the toolbar. The click on the “Diagnostics” tab, click the “Align” button for the automatic alignment to begin. When the laser has finished aligning, click the “Laser Verification” button. Follow the guide to remove the accessory and click OK. Click the “Start Verification” button and click “OK” once the verification has finished. There is no printed documentation for this maintenance.

- ATR Check

Load the Smart iTX accessory (the ATR accessory) and select “ValPro Qualification” from the “Analyze” menu. From the drop-down menu, select “Smart iTX accessory-PHEUR” and click the “Qualify” button on the far right. A pop-up will be displayed asking to collect background, click “OK” to collect background. Follow the on screen guide to load the polystyrene, lower/lock the arm in place and click “OK”. Once the check is finished, the report will be displayed on the screen. Click “Print” and then “Close”. Review the report for any issues and submit to the Quality Manager for review.

- POLYSTYRENE CHECK

A scan of a traceable polystyrene film shall be done at least once per week. The polystyrene system check will be performed in the same manner as casework analysis, outlined in the previous section, and evaluated using the peaks in the table below. All five (5) peaks must fall within +/- 4 cm⁻¹ for the instrument to pass. If any peak(s) fall outside the ‘passing range’ the instrument will be removed from service until all peaks fall within the defined passing range and the polystyrene must have a library match of 80 or greater to an approved library. Indicate if the check passed or failed on the print out and retain the printed spectra and library match in the maintenance binder.

Peaks for Comparison
694
1028
1491
1601
3025

MONTHLY MAINTENANCE

- Run and print a new background**



SOLID DOSE DRUG PROCEDURES

- **Main System Check**

Load the transmission accessory into the instrument. Select “ValPro Qualification” from the “Analyze” menu. From the drop-down menu, select “Nicolet iS20 KBr-Factory (CP, JP, PHEUR, PV, USP)-PV”. Click the “Qualify” button on the far right and allow the process to run for about 15 to 20 minutes. Once the check is finished, the report will be displayed on the screen. Click “Print” and then “Close”. Review the report for any issues and submit to the Quality Manager for review.

- **Software Checks**

Select “ValPro Qualification” from the “Analyze” menu. From the drop-down menu, select “Quantification & Algorithms 2019-ALL”. Click the “Qualify” button on the far right. Once the check is finished, the report will be displayed on the screen. Click “Print” and then “Close”. Review the report for any issues and submit to the Quality Manager for review.

- **Back up data**

Copy all case work and maintenance data from the previous month and transfer it to the appropriately labeled folder on the external hard drive. Transfer that data to the K drive for network storage.

ANNUAL MAINTENANCE

Preventative Maintenance performed by competent vendor, when possible.

All maintenance shall be recorded on the maintenance checklist or the maintenance binder for the instrument. Copies of maintenance data from the current year are retained in a binder located near the FTIR. Maintenance data from past years are stored either in a designated folder in the Evidence Room or are archived or retained by the Quality Manager in digital format.



SOLID DOSE DRUG PROCEDURES

Revision Table		
Number	Date	Changes Made
1*	12/23/2020	<p>Table of contents corrected</p> <p>Minor spelling, grammer, structure changes made throughout</p> <p>Section II C: updated to include extraction procedural blanks</p> <p>Section II E c and d: references to use of uncertainty associated with calibrated weights removed</p> <p>Section II Combined weight section: added the option of applying the most conservative number of weighing events to the total number of items tested</p> <p>Section III A 3: added language and examples of major and minor discrepancies</p> <p>Section III A 4: added guidance if seals are not intact</p> <p>Section III B 2: all hypergeometric sampling tables corrected, and references updated</p> <p>Section III C 1: Drugs.com added to tables</p> <p>Section IV A: items to be included in case notes updated</p> <p>Section IV B: chain of custody added to items included in casefile</p> <p>Section IV C: sample preparation updated to include a procedural blank and changed use of SDD solvent to "appropriate" solvent for blanks</p> <p>Section VI A: PPE updated, internal standard updated to include DFTPP as an option and methods updated to include Rapid Drug and Steroid as options</p> <p>Section VI B: step specifying preparing a tube as a procedural blank added</p> <p>Section VI B: PPE added</p> <p>Section VI C-G: title lettering updated for all, PPE section updated for all, additional solvet options added, extraction procedural blank language added, and sample preparation updated for all</p> <p>Section VI D: extraction tables updated to reflect current procedures</p> <p>Section VI E 2: weighing sample language removed</p> <p>Appendix A 4: language about subtraction added, reference to HETLSDD library added, S/N report section added</p> <p>Revision Table added</p>
2	3/15/21	<p>Section III, B, 2 was added to include a reserve weight definition and procedure</p>



SOLID DOSE DRUG PROCEDURES

		Section VC was updated to note that sample solution guidance could be found in the Specific Analytical Procedures sections.
3	04/29/2021	References to Marijuana were removed throughout and replaced with either cannabis or delta-9 THC. Report wording was included in Section VI A to address reporting of cannabis samples.
4	03/08/2022	<ul style="list-style-type: none"> - Updated evidence room numbering throughout - Section II B updated to include the process for updating standards on the GC/MS and FTIR - Section III A updated to state initials shall be required on across the seal of a package, and noted if not present. Updated to include evidence photos - Removed UoM procedure as there is a separate policy document. Section was revised to reference separate policy. - Section III C 1 was updated to include the limitations of a Category A technique. - Updated analysis of syringes throughout due to updated statute. Will be analyzed customer request only now. - Blank requirement added to section VI A 3 - Minor formatting, grammar, and spelling updates throughout - Section IV B: updated following observed PT - Added SDD Mix C as option throughout - Section VI D: added requirement of taking the weight of at least one pill/capsule/films - Section VI E: Corrected preparation of LSD/LAMPA standards - Section VI F: Corrected blank preparation - Section VI G: added option for edibles procedure - Removed GHB method from GC/MS section - Update FTIR Appendix to better match process
5	3/10/22	<ul style="list-style-type: none"> - Corrected Section II.B New Lot Number of Existing Compounds to required one print out from both instruments for the library entry review. - Corrected numbering issues in FTIR Appendix
6	03/29/22	<ul style="list-style-type: none"> - Section I A: updated to include a description of the evidence on the contract, and included a process for repackaging evidence in new packaging after examination - Section II D: Processing blanks updated to include procedure relating to updating of a standard



SOLID DOSE DRUG PROCEDURES

		<ul style="list-style-type: none"> - Section III A 3: Noted that chemical abbreviations are listed in the Chemical Hygiene Plan and that a state controlled camera should be used for photographing evidence - III A 4: updated to include that all seals shall be checked for initials and noted if not present - III B 3: updated to include deviations shall be communicated to customer and included on the COA - III C 5: updated to include guidance for reporting inconclusive samples - V : update to include customer communications relating to deviations - V F: updated to include second option for mushroom extraction
7	04/25/2022	- Updated Iodo TLC Spray to list 8% Platinic Chloride
8	06/28/2022	- Updated sections relating to FTIR for implementation of new Nicolete iS20 FTIR instrument
9	07/01/2022	- Updated FTIR section to include required scan region and corrected the word wavenumber to resolution in the blank and sample evaluation section.
10	08/09/2022	<ul style="list-style-type: none"> - Section I. A. changed room number to room description to prepare for move. Updated guidance for resealing packages. - Section II. B. added reference to SOP Manual and Quality Manual for standard handling and storage.
11	10/01/2022	<ul style="list-style-type: none"> - Removed Color Testing, removed all TLC sprays and systems, with the exception of the general drug screen system and Iodo spray, and removed Quechers ediles extraction. These are no longer active procedures. - Section I A updated to clarify that samples taken of evidence for testing are not tracked on the chain of custody.
12	03/31/23	<ul style="list-style-type: none"> - Added S/N criteria as an acceptance criteria for GCMS compound evaluation - Updated sample calculation of UoM to clarify what should be considered - Added procedure for daily/weekly balance checks - Corrected table of contents and section headers to be consistent for Section VI - Section VI. G. Waste was added. Includes specific



SOLID DOSE DRUG PROCEDURES

		waste instructions for all processes - Reference to use of ether removed and replaced with SDD Mix.
--	--	---

*revisions prior to Dec 23, 2020 are listed in the Version History section of SharePoint